Cardio Diagnostics Holdings, Inc. Deferred Federal Income Tax Expense (Benefit)
Cardio Diagnostics Holdings, Inc. (CDIO) reported Deferred Federal Income Tax Expense (Benefit) of $30.42 thousand for the 7-month period ending 2021-12-31, per its 10-K filed 2022-03-31.
Discontinued › Expense Statement › Income Tax
us-gaap:DeferredFederalIncomeTaxExpenseBenefit · last filed 2022-03-31
- 2021-12-31: Deferred Federal Income Tax Expense (Benefit) 7 month $30.42K.
| Period end | Deferred Federal Income Tax Expense (Benefit) 7 month |
|---|---|
| 2021-12-31 | $30.42K 10-K · filed 2022-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VOLITIONRX LTD (VNRX) | $0.003B | -0.64 | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |